Replimune/$REPL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Replimune
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Ticker
$REPL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
479
Website
Replimune Metrics
BasicAdvanced
$243M
-
-$3.07
0.68
-
Price and volume
Market cap
$243M
Beta
0.68
52-week high
$14.80
52-week low
$2.68
Average daily volume
6.6M
Financial strength
Current ratio
7.952
Quick ratio
7.818
Long term debt to equity
17.358
Total debt to equity
18.316
Interest coverage (TTM)
-32.92%
Profitability
EBITDA (TTM)
-253.924
Effective tax rate (TTM)
-0.19%
Management effectiveness
Return on assets (TTM)
-31.26%
Return on equity (TTM)
-62.58%
Valuation
Price to book
0.58
Price to tangible book (TTM)
0.58
Price to free cash flow (TTM)
-1.276
Free cash flow yield (TTM)
-78.39%
Free cash flow per share (TTM)
-246.93%
Growth
Earnings per share change (TTM)
-5.31%
3-year earnings per share growth (CAGR)
10.73%
What the Analysts think about Replimune
Analyst ratings (Buy, Hold, Sell) for Replimune stock.
Replimune Financial Performance
Revenues and expenses
Replimune Earnings Performance
Company profitability
Replimune News
AllArticlesVideos
REPL LEGAL UPDATE: Replimune Group, Inc. Sued after FDA Response Letter -- Investors with Losses are Notified to Contact BFA Law before September 22 Class Action Deadline
Business Wire·3 days ago
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Business Wire·4 days ago
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc. Investors – REPL
Business Wire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Replimune stock?
Replimune (REPL) has a market cap of $243M as of July 28, 2025.
What is the P/E ratio for Replimune stock?
The price to earnings (P/E) ratio for Replimune (REPL) stock is 0 as of July 28, 2025.
Does Replimune stock pay dividends?
No, Replimune (REPL) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Replimune dividend payment date?
Replimune (REPL) stock does not pay dividends to its shareholders.
What is the beta indicator for Replimune?
Replimune (REPL) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.